The Ministry of Health and Prevention (MoHAP) has approved the use of Sinopharm CNBG's new recombinant protein vaccine.
The study conducted for the vaccine included individuals that were vaccinated with two doses of the Sinopharm CNBG's inactivated vaccine.
The efficacy of the vaccine was at 100% with neutralising antibodies and had no side effects on individuals.
The study has also shown an immune response against variants of the virus.
The vaccine, produced and distributed by Hayat Biotech, will be available to the public from January 2022, and will help in ensuring the safety of individuals against the virus.